Liberman identifies CD28 signaling boosts antitumor function in CAR T cells, suggesting enhanced treatment potential.
Liberman and colleagues identify endogenous CD28 signaling as a regulator of 4-1BB chimeric antigen receptor (CAR) T-cell function by promoting metabolic fitness, proliferation, and sustained antitumor function. These findings highlight the cooperative integration of CD28 and 4-1BB signaling to harness CAR T-cell potency, persistence, and therapeutic efficacy. See related article by Lieberman et al., p. XX .
No takes yet. Share an insight, caveat, or question.
Hamieh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: